Julie Maltzman, M.D.

Dr. Julie Maltzman is a medical oncologist with broad experience built over 20 years across all phases of drug development. She joined IconOVir in Oct 2022 from a VP, Global Head of GI Cancers and Cancer Immunotherapy role at Roche/Genentech. There, Dr. Maltzman oversaw the successful registration and commercialization of Atezolizumab and Bevacizumab for HCC. […]

IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer

SAN DIEGO, CA., Oct. 10, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Julia (Julie) Maltzman, M.D., as its Chief Medical Officer. Dr. Maltzman brings over three decades of experience as […]